SpragueS.M.Renal bone disease.Curr Opin Endocrinol Diabetes Obes2010; 17: 535–9.
2.
Kidney Disease Improving Global Outcomes.KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).Kidney Int Suppl2009: S1–130.
3.
AlemA.M., SherrardD.J., GillenD.L., WeissN.S., BeresfordS.A., HeckbertS.R.Increased risk of hip fracture among patients with end-stage renal disease.Kidney Int2000; 58: 396–9.
4.
DaneseM.D., KimJ., DoanQ.V., DylanM., GriffithsR., ChertowG.M.PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis.Am J Kidney Dis2006; 47: 149–56.
5.
MallucheH.H., MawadH.W., Monier-FaugereM.C.Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients.J Bone Miner Res2011; 26: 1368–76.
6.
GarrettG., SardiwalS., LambE.J., GoldsmithD.J.PTH — a particularly tricky hormone: why measure it at all in kidney patients?Clin J Am Soc Nephrol2013; 8: 299–312.
7.
BrownR.C., AstonJ.P., WeeksI., WoodheadJ.S.Circulating intact parathyroid hormone measured by a two-site immunochemiluminometric assay.J Clin Endocrinol Metab1987; 65: 407–14.
8.
NussbaumS.R., ZahradnikR.J., LavigneJ.R., BrennanG.L., Nozawa-UngK., KimL.Y.Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia.Clin Chem1987; 33: 1364–7.
9.
LevinA., BakrisG.L., MolitchM., SmuldersM., TianJ., WilliamsL.A.Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease.Kidney Int2007; 71: 31–8.
10.
LepageR., RoyL., BrossardJ-H, RousseauL., DoraisC., LazureC.A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples.Clin Chem1998; 44: 805–9.
11.
BrossardJ.H., LepageR., CardinalH., RoyL., RousseauL., DoraisC.Influence of glomerular filtration rate on non-(1-84) parathyroid hormone (PTH) detected by intact PTH assays.Clin Chem2000; 46: 697–703.
12.
HocherB., ArmbrusterF.P., StoevaS., ReichetzederC., GronH.J., LiekerI.Measuring parathyroid hormone (PTH) in patients with oxidative stress — do we need a fourth generation parathyroid hormone assay?PLoS One2012; 7: e40242.
13.
HocherB., OberthurD., SlowinskiT., QuerfeldU., SchaeferF., DoyonA.Modeling of oxidized PTH (oxPTH) and non-oxidized PTH (n-oxPTH) receptor binding and relationship of oxidized to non-oxidized PTH in children with chronic renal failure, adult patients on hemodialysis and kidney transplant recipients.Kidney Blood Press Res2013; 37: 240–51.
14.
HanonE.A., SturgeonC.M., LambE.J.Sampling and storage conditions influencing the measurement of parathyroid hormone in blood samples: a systematic review.Clin Chem Lab Med2013; 51: 1925–41.
15.
SturgeonC.M., SpragueS.M., MetcalfeW.Variation in parathyroid hormone immunoassay results — a critical governance issue in the management of chronic kidney disease.Nephrol Dial Transplant2011; 26: 3440–5.
16.
AlmondA., EllisA.R., WalkerS.W.Current parathyroid hormone immunoassays do not adequately meet the needs of patients with chronic kidney disease.Ann Clin Biochem2012; 49: 63–7.
17.
VulpioC., BossolaM., SperanzaD., ZuppiC., LucianiG., Di StasioE.Influence of blood sampling site on intact parathyroid hormone concentrations in hemodialysis patients.Clin Chem2010; 56: 489–90.
18.
MooreC., YeeJ., MallucheH., RaoD.S., Monier-FaugereM.C., AdamsE.Relationship between bone histology and markers of bone and mineral metabolism in African-American hemodialysis patients.Clin J Am Soc Nephrol2009; 4: 1484–93.
19.
DrechslerC., GrootendorstD.C., BoeschotenE.W., KredietR.T., WannerC., DekkerF.W.Changes in parathyroid hormone, body mass index and the association with mortality in dialysis patients.Nephrol Dial Transplant2011; 26: 1340–6.
20.
DrechslerC., KraneV., GrootendorstD.C., RitzE., WinklerK., MarzW.The association between parathyroid hormone and mortality in dialysis patients is modified by wasting.Nephrol Dial Transplant2009; 24: 3151–7.
21.
RodriguezM., LorenzoV.Parathyroid hormone, a uremic toxin.Semin Dial2009; 22: 363–8.
22.
GardhamC., StevensP.E., DelaneyM.P., LeRouxM., ColemanA., LambE.J.Variability of parathyroid hormone and other markers of bone mineral metabolism in patients receiving hemodialysis.Clin J Am Soc Nephrol2010; 5: 1261–7.
23.
Gal-MoscoviciA., PopovtzerM.M.New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels.Clin Nephrol2005; 63: 284–9.
24.
BarretoF.C., BarretoD.V., MoysesR.M., NevesK.R., CanzianiM.E., DraibeS.A.K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients.Kidney Int2008; 73: 771–7.
25.
BhuriyaR., LiS., ChenS.C., McCulloughP.A., BakrisG.L.Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP).Am J Kidney Dis2009; 53: S3–10.
26.
PalmerS.C., HayenA., MacaskillP., PellegriniF., CraigJ.C., ElderG.J.Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis.JAMA2011; 305: 1119–27.
27.
TonelliM., CurhanG., PfefferM., SacksF., ThadhaniR., MelamedM.L.Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality.Circulation2009; 120: 1784–92.
28.
AbramowitzM., MuntnerP., CocoM., SouthernW., LotwinI., HostetterT.H.Serum alkaline phosphatase and phosphate and risk of mortality and hospitalization.Clin J Am Soc Nephrol2010; 5: 1064–71.
29.
KrishnamurthyV.R., BairdB.C., WeiG., GreeneT., RaphaelK., BeddhuS.Associations of serum alkaline phosphatase with metabolic syndrome and mortality.Am J Med2011; 124: 566 e561–567.
30.
BlayneyM.J., PisoniR.L., Bragg-GreshamJ.L., BommerJ., PieraL., SaitoA.High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death.Kidney Int2008; 74: 655–63.
31.
RegidorD.L., KovesdyC.P., MehrotraR., RambodM., JingJ., McAllisterC.J.Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients.J Am Soc Nephrol2008; 19: 2193–203.
32.
KovesdyC.P., UrecheV., LuJ.L., Kalantar-ZadehK.Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD.Nephrol Dial Transplant2010; 25: 300–11.
33.
TaliercioJ.J., ScholdJ.D., SimonJ.F., ArrigainS., TangA., SaabG.Prognostic importance of serum alkaline phosphatase in CKD stages 3–4 in a clinical population.Am J Kidney Dis2013; 62: 703–10.
34.
MolnarM.Z., KovesdyC.P., MucsiI., SaluskyI.B., Kalantar-ZadehK.Association of pre-kidney transplant markers of mineral and bone disorder with post-transplant outcomes.Clin J Am Soc Nephrol2012; 7: 1859–71.
35.
Kalantar-ZadehK., KuwaeN., RegidorD.L., KovesdyC.P., KilpatrickR.D., ShinabergerC.S.Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients.Kidney Int2006; 70: 771–80.
36.
RheeC.M., MolnarM.Z., LauW.L., RavelV., KovesdyC.P., MehrotraR.Comparative mortality-predictability using alkaline phosphatase and parathyroid hormone in patients on peritoneal dialysis and hemodialysis.Perit Dial Int2014; 34: 732–48.
37.
LiuX., GuoQ., FengX., WangJ., WuJ., MaoH.Alkaline phosphatase and mortality in patients on peritoneal dialysis.Clin J Am Soc Nephrol2014; 9: 771–8.
38.
FeinP.A., AsadiS., SinghP., HartmanW., StutoS., ChattopadhyayJ.Relationship between alkaline phosphatase and all-cause mortality in peritoneal dialysis patients.Adv Perit Dial2013; 29: 61–3.
39.
LambE.J., BrowneM., JohnW.G., PriceC.P.Alkaline phosphatase activity measurement in the UK by AMP-buffered methods: an appraisal of current practice.Ann Clin Biochem1998; 35(1): 120–7.
40.
DrechslerC., VerduijnM., PilzS., KredietR.T., DekkerF.W., WannerC.Bone alkaline phosphatase and mortality in dialysis patients.Clin J Am Soc Nephrol2011; 6: 1752–9.
41.
KobayashiI., ShidaraK., OkunoS., YamadaS., ImanishiY., MoriK.Higher serum bone alkaline phosphatase as a predictor of mortality in male hemodialysis patients.Life Sci2012; 90: 212–18.
42.
HillC.S., WolfertR.L.The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase.Clin Chim Acta1990; 186: 315–20.
43.
PanigrahiK., DelmasP.D., SingerF., RyanW., ReissO., FisherR.Characteristics of a two-site immunoradiometric assay for human skeletal alkaline phosphatase in serum.Clin Chem1994; 40: 822–8.
44.
BroylesD.L., NielsenR.G., BussettE.M., LuW.D., MizrahiI.A., NunnellyP.A.Analytical and clinical performance characteristics of Tandem-MP Ostase, a new immunoassay for serum bone alkaline phosphatase.Clin Chem1998; 44: 2139–47.
45.
SardiwalS., MagnussonP., GoldsmithD.J., LambE.J.Bone alkaline phosphatase in CKD-mineral bone disorder.Am J Kidney Dis2013; 62: 810–22.
46.
ManghatP., FraserW.D., WierzbickiA.S., FogelmanI., GoldsmithD.J., HampsonG.Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease.Osteoporos Int2009; 21: 1853–61.
47.
SardiwalS., GardhamC., ColemanA.E., StevensP.E., DelaneyM.P., LambE.J.Bone-specific alkaline phosphatase concentrations are less variable than those of parathyroid hormone in stable hemodialysis patients.Kidney Int2012; 82: 100–5.
48.
ChertowG.M., BlockG.A., Correa-RotterR., DruekeT.B., FloegeJ., GoodmanW.G.Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.N Engl J Med2012; 367: 2482–94.
49.
CavalierE., SouberbielleJ.C., GadisseurR., DuboisB., KrzesinskiJ.M., DelanayeP.Inter-method variability in bone alkaline phosphatase measurement: Clinical impact on the management of dialysis patients.Clin Biochem2014; 47(13–14): 1227–30.
